1199-64-0

Basic information

• Product Name: 1H-pyrrole-2,5-dicarboxylic acid monomethyl ester
• Synonyms: 1H-pyrrole-2,5-dicarboxylic acid monomethyl ester
• CAS NO: 1199-64-0
• Molecular Weight: 169.137
• Mol File: 1199-64-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 241-242 °C
• Boiling Point: 408.6±30.0 °C(Predicted)
• Density: 1.431±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1H-pyrrole-2,5-dicarboxylic acid monomethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-pyrrole-2,5-dicarboxylic acid monomethyl ester(1199-64-0)
• EPA Substance Registry System: 1H-pyrrole-2,5-dicarboxylic acid monomethyl ester(1199-64-0)

Safety Data

• Hazardous Substances Data: 1199-64-0(Hazardous Substances Data)

Usage

Ester derivative

pyrrole-2,5-dicarboxylic acid The compound is derived from pyrrole-2,5-dicarboxylic acid by replacing one of the carboxylic acid groups with a methyl ester group.

Common use

organic synthesis and pharmaceutical research The compound is frequently used in the synthesis of new organic compounds and as a building block in the development of pharmaceuticals.

Applications

production of pharmaceuticals, dyes, and agricultural chemicals The compound is utilized in the manufacturing of various products, including medications, coloring agents, and chemicals for agricultural purposes.

Intermediate in manufacturing

fine chemicals and specialty materials 1H-pyrrole-2,5-dicarboxylic acid monomethyl ester serves as a precursor in the production of other chemical compounds and materials with specific properties.

Potential biological activity

therapeutic uses in treatment of diseases The compound is being investigated for its possible effects on biological systems, with the aim of discovering its potential applications in treating various diseases.

Versatile compound

important in chemistry and medicine 1H-pyrrole-2,5-dicarboxylic acid monomethyl ester has a wide range of applications and is significant in both the fields of chemistry and medicine due to its unique properties and potential uses.

Upstream product

• 35302-72-8 pyrrol-2-yl trichloromethyl ketone 
• 1193-62-0 methyl Pyrrole-2-carboxylate 
• 74-88-4 methyl iodide 
• 1197-13-3 methyl 5-formyl-1H-pyrrole-2-carboxylate 

Downstream Products

• 347362-31-6 5-chlorocarbonyl-1H-pyrrole-2-carboxylic acid methyl ester 
• 1408284-18-3 3,5-bis((5-(butylcarbamoyl)-1H-pyrrole-2-carboxamido)methyl)phenyl 5-(dimethylamino)naphthalene-1-sulfonate 
• 1408284-24-1 N₂,N₂'-(5-(tert-butyldimethylsilyloxy)-1,3-phenylene) bis(methylene)bis(N₅-butyl-1H-pyrrole-2,5-dicarboxamide) 
• 852200-64-7 1H-pyrrole-2,5-dicarboxylic acid bis-phenylamide 

Relevant articles and documents

The role of N-terminal heterocycles in hydrogen bonding to α-chymotrypsin

A series of dipeptide aldehydes containing different N-terminal heterocycles was prepared and assayed in vitro against α-chymotrypsin to ascertain the importance of the heterocycle in maintaining a β-strand geometry while also providing a hydrogen bond do

Isomeric chiral pyrrole diamides and their efficacy in enantioselective sensing of tartrate in sol–gel medium

Pyridinium motif-based chiral pyrrole diamide clefts 1 and 2 have been designed and synthesized for chiral recognition of hydroxycarboxylates in sol–gel medium. Of the two isomeric chiral receptors, receptor 1 shows selective sensing of D-tetrabutylammonium tartrate over its mirror image isomer in CH3CN. The isomeric receptor 2 did not show any enantioselectivity in the recognition. Moreover, the receptor 1 validates prompt visual sensing of D-tartrate through gelation. The recognition properties of the receptors have been studied by fluorescence, UV–vis,1H NMR and CD spectroscopic methods.

Pyrrole-derivatives as factor Xa inhibitors

The present invention relates to compounds of the formulae I and Ia, wherein R0 ; R1 ; R2 ; R3 ; R4; R22, Q; V, G and M have the meanings indicated in the claims. The compounds of the formulae I and Ia are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ia, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.